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Treatment of tuberculosis (TB) relies on a combination of bactericidal and sterilising drugs administered
for an adequate duration of time to ensure synergy of action in order to achieve definitive cure and
prevent the selection of drug-resistant mutants [1]. Current treatment regimens are, however, not ideal,
due to long duration and some toxicity. Particularly unsatisfactory are regimens recommended for the
treatment of multidrug-resistant (MDR) (a form of tuberculosis with strains resistant to at least rifampicin
and isoniazid) or extensively drug-resistant (XDR)-TB that have lower efficacy, significant toxicity, longer
duration and high costs [2–5]. New TB drugs and regimens are needed to improve cure rates, lessen
toxicity, and shorten the treatment of both drug-susceptible (DS) and drug-resistant TB (currently at least
6 and 9–20 months, respectively) [6, 7]. Two TB drugs (bedaquiline and delamanid) [8, 9] have become
available and are recommended by the World Health Organization (WHO) for the treatment of MDR-TB
under certain conditions [10, 11]. However, these drugs have so far been tested for efficacy as add-ons to
conventional WHO-recommended treatment for MDR-TB only, and their optimal use in combinations
that could lead to increased treatment efficacy while improving safety and reducing toxicity still remains to
be established [12–14]. Other novel compounds, as well as re-purposed drugs, are currently in clinical
trials, either as part of novel treatment regimens or in addition to the current standard of care [15].
The development of TB drugs is lengthy and costly: if new drugs are added to or substituted within
existing regimens one at a time, it would take 15–20 years to develop a new regimen of three to four new
drugs to treat TB [6, 7]. Developing a novel regimen without going through intermediary steps to obtain
individual drug approvals separately and only then beginning to test novel combinations would
substantially reduce the duration of the whole regimen development. It will also reduce the expenditures
needed to make significant progress in the field [16, 17]. Combination regimens including one or more
promising new or re-purposed drugs should be tested early in the clinical development process to identify
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optimal combination regimens for the treatment of DS and drug-resistant TB to be tested in phase II and
III trials.
Development of shorter and simpler regimens combining new and existing drugs requires detailed
information on their respective activity, safety and toxicity [18–20], including potential drug–drug
interactions, propensity for development of drug resistance while on therapy [21–24] and clinical use in
specific patient populations (such as persons with HIV/AIDS, pregnant women and children [4]). Given
these complexities, target product profiles (TPPs) are usually composed as a guide to identifying desired
product attributes and characteristics to be considered during the development process [25].
The aim of this editorial is to discuss the concept and role of TPPs for new anti-TB regimens, referred
hereafter as “target regimen profiles” (TRPs), and describe the outcomes of the recent process led by
WHO to develop these profiles [26].
Objective and role of TRPs for TB treatment
Considering the need for safer, simpler, more efficacious and accessible treatment regimens for all forms of
TB, TRPs for TB treatment have been developed in a synergistic effort by the WHO Global TB
Programme and the WHO Task Force on New TB Drug Policy Development, with the contribution of a
large range of experts and stakeholders.
The novelty of this approach is to have the goal of the treatment regimen in mind very early in the process
of drug development, and relies on the fact that TB drug research and development should move rapidly
towards developing and testing TB regimens rather than individual drugs. On this basis, TRPs for TB
treatment have been developed to describe the targets and specifications that developers should meet for
appropriate performance and adequate operational characteristics of new TB treatment regimens,
considering the needs of end-users. At a minimum, the TRPs specify the clinical indication of the regimen(s),
the goal to be met, the measure of efficacy, the main safety aspects, the target population that will receive
the treatment and the intended end-users. In addition, they should outline the most important
performance and operational characteristics, with the term “minimal” used to refer to the lowest
acceptable output for a characteristic and “optimal” used to refer to the ideal target for a characteristic.
The optimal and minimal characteristics define a range: it is therefore expected that new TB treatment
regimens meet at least all of the required minimal characteristics and, preferably, as many of the optimal
characteristics as possible.
The target audience includes the pharmaceutical industry, academia, research institutions, product
development partnerships, nongovernmental organisations, and potential investors and donors [26].
Methods to develop the TRPs
The initial profiles were drafted on the basis of outcomes of expert group meetings, an initial stakeholder
survey, mathematical modelling, and interviews of a wide range of experts and stakeholders.
First, the candidate regimen will consist of a minimum combination of drugs targeting all possible
populations of bacilli in the patient (i.e. including those proliferating in local acidic conditions or in states
of brief sporadic metabolism or replication) and having a clear sterilising effect (so as to ensure
nonrelapsing cure within a few months after starting the treatment). In defining the potential TRPs, the
Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA) was assumed to be widely available as a “triage test”
under routine programmatic conditions, based on the current worldwide implementation process and
scale-up. In that scenario, whether the bacilli harboured by the TB patient are rifampicin susceptible or
not will be known from the start. Subsequently, profiles were developed for the treatment of
rifampicin-susceptible (RS) and rifampicin-resistant (RR)-TB, respectively, the latter being considered a
proxy for MDR-TB. In addition, premised on the potential for a regimen of three to four entirely new
anti-TB drugs (i.e. excluding rifampicin, isoniazid and pyrazinamide) for which minimal or no resistance
would exist as a result of prior use in the community, a TRP was developed for “pan-TB treatment”. This
regimen would be implemented in a simple and streamlined manner without need for drug-susceptibility
testing (DST) or for a separate treatment pathway for patients with at least RR-TB (then, whichever rapid
tests of drug resistance might be developed/available, they would suitably come as a complement to further
refine the patients’ needs given the resistance profile).
Mathematical modelling was then used to estimate the relative impact of selected regimen characteristics
on population-wide TB incidence and mortality. The selected characteristics were 1) efficacy (achieving
high nonrelapsing cure rates), 2) treatment duration, 3) adherence, 4) medical contraindications, 5) barrier
to resistance and 6) baseline prevalence of resistance to drugs in the regimen. The influence of each
characteristic on expected incidence and mortality outcomes was evaluated as the characteristic ranged
from a minimum acceptable value to an optimistic target.
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Then, an Internet-based survey was conducted to identify what would be the priority attributes that a wide
audience of stakeholders would value for the development of the TRPs. It contained core questions in four
main categories (efficacy, safety, adherence and operational considerations) [26]. Finally, a web-based
Delphi consultation was organised to gather input from the larger TB control and research community,
and a consensus meeting took place to review the draft target profiles. The final document was formally
launched at the European Respiratory Society International Congress in London (figure 1).
The details of the three TRPs are presented below.
TRP for RS-TB
Rationale
Despite the wide availability of a highly efficacious, low-cost regimen of 6 months’ duration for the
treatment of RS-TB, improvements are still needed if we are to achieve the WHO targets set within the
context of the End TB Strategy [27]. The current 6-month regimen has several limitations including
drug-related adverse events, challenging drug–drug interactions (in particular, with some antiretroviral
medicines) and difficulty in ensuring adherence for the full duration of treatment across all settings. By
improving adherence to treatment, shorter regimens would result in better outcomes and lower risk of
acquisition of resistance, faster recovery, a shorter period at risk of side-effects, and lower patient and
programme costs [6, 7]. Future RS-TB regimens would ideally also be active against strains that are
monoresistant to any other first-line drug except rifampicin.
Key attributes
The characteristics of the TRP for RS-TB treatment are summarised in table 1. To achieve these, it will be
necessary to use multiple-drug combinations with both bactericidal and sterilising efficacy according to
well established principles of TB chemotherapy [1] to assure durable and relapse-free cure.
TRP for RR-TB
Rationale
About 480000 new MDR-TB cases and an additional 100000 cases of RR disease were estimated to have
occurred in the world in 2015 [28]. However, only 125000 MDR-TB patients were reported by countries
to have initiated treatment [28]. The conformity of these regimens to those recommended by WHO and
the quality of medicines used is usually unknown, and only about one half of patients treated globally is
reported to complete treatment successfully [28, 29].
In the absence of formal randomised controlled trials, the conventional (or longer) MDR-TB treatment
recommended by WHO (based on a minimum of five drugs) is the result of expert opinion based on
observational studies [30] and there has been no head-to-head comparison of one MDR regimen versus
another MDR regimen of any kind (of note, a trial is currently underway to evaluate a short MDR
regimen versus the 20-month WHO standard) [31, 32]. As a consequence, using the GRADE system
definitions, the available evidence is generally of “low” or “very low” quality [33]. In addition, the
complexity and limited efficacy of current regimens may predispose to development of additional
resistance [23, 24]. Finally, it is imperative to lower the cost of MDR-TB regimens to make them accessible
in the poorest settings [16, 17].
FIGURE 1 Picture of the official
launch of the World Health
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The newly WHO-recommended shorter MDR-TB treatment regimen of 9–12 months has shown rates of
relapse-free cure topping 85% in different Asian and African countries as part of observational studies
(WHO recommends the use of this regimen conditionally among selected MDR/RR-TB patients, i.e.
pulmonary TB cases with no previous exposure or known resistance to fluoroquinolones or injectable
drugs) [34–36]. This regimen is composed of seven drugs (five of which are also part of the longer
regimen) known to have good bactericidal activity against MDR-TB strains. The two newly available
TABLE 1 Characteristics of the target regimen profile for rifampicin-susceptible (RS) tuberculosis (TB)
Attribute Minimum# Optimum¶
1 Indication Active against RS M. tuberculosis strains Active against RS M. tuberculosis strains including
monoresistance to any drug except rifampicin
2 Efficacy and duration of
treatment
A regimen of 4 months or less with efficacy not
inferior+ to the current standard of care
6-month regimen for DS-TB
A regimen of 2 months or less with efficacy not
inferior to the current standard of care 6-month
regimen for drug-susceptible TB
3 Target population All age groups, irrespective of HIV status All age groups, irrespective of HIV status
4 Safety and tolerability Incidence and severity of adverse events no worse
than for standard of care
No more than monthly clinical monitoring and no
laboratory monitoring for drug toxicity needed
except in special populations (pre-existing liver
disease, diabetes, etc.)
Incidence and severity of adverse events better than
for standard of care
No active clinical monitoring and no laboratory
monitoring for drug toxicity needed except in
special populations (pre-existing liver disease,
diabetes, etc.)
5 DDI and metabolism Ability to use safely without active laboratory
testing or monitoring with:
First-line ART regimen(s)
Rifamycins (if a rifamycin is included in the
regimen)
Drugs that induce or inhibit P450 liver enzymes
Proarrhythmic drugs that prolong QT/QTc interval
No dose adjustment with other medications and
ability to use safely without active laboratory
testing or monitoring with:
First-line ART regimens and co-trimoxazole
Rifamycins (if a rifamycin is included in the
regimen)
Drugs that induce or inhibit P450 liver enzymes
Proarrhythmic drugs that prolong QT/QTc interval
6 Formulation dosage and route
of administration
Formulation to be oral for all drugs in regimen,
including paediatrics
Well tolerated and simple to administer to
enhance adherence
Exclusively oral delivery (preferably once daily);
ideally without the need for weight band
adjustments, and suitable for fixed dose
combination formulations
Parenteral formulations would allow to treat severe
cases
3 or fewer pills per day
7 Stability/shelf life Without cold storage requirements, with shelf
lives of at least 3 years for all the drugs
comprising the regimen
Without cold storage requirements, with shelf lives
of at least 5 years for all the drugs comprising
the regimen
8 Special populations Safe on a wide range of patients (children,
pregnant women and patients with
comorbidities (HIV, viral hepatitis, diabetes,
etc.) and low to no drug–drug interactions
For women of child bearing potential and pregnant
women, availabile human data that do not
indicate that the component drugs increase the
overall risk of structural abnormalities and the
drugs are safe with breastfeeding





Each component of the regimen should have no
greater mutation rate (in unselected bacterial
population) than 1 in 107 mutations per
bacterium per generation
New resistance to one or more drugs in the
regimen emerges in <1% of treatment courses
when taken as prescribed and when no
pre-existing resistance to the drugs in the
regimen exists
Each component of the regimen should have no
greater mutation rate (in unselected bacterial
population) than 1in 109 mutations per bacterium
per generation
Essentially no acquired resistance (<0.01%) when
regimen is taken as prescribed and no
pre-existing resistance to the drugs in the
regimen exists
M. tuberculosis: Mycobacterium tuberculosis; ART: antiretroviral therapy; DS: drug-susceptible; DDI: drug–drug interaction. #: should be considered
as a potential go/no go decision point; ¶: should reflect what is needed to achieve broader, deeper, quicker global health impact; +: the term
“not inferior” is intentionally used in place of noninferiority, which is a trials design and methodology term.
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agents, bedaquiline [9, 10] and delamanid [8, 11], have shown potential to improve the efficacy of MDR
regimens on top of the conventional WHO-recommended regimen. Some new drugs currently in the drug
development pipeline (e.g. pretomanid and sutezolid) [37] show promise for use in MDR-TB regimens
together with re-purposed drugs (e.g. linezolid, clofazimine and fluoroquinolones) [3, 38]. The goal of this
TRP is to identify a suitable combination regimen early in the development process that would be safe,
efficacious and of short duration [39].
Key attributes
The characteristics of this TRP are summarised in table 2. The optimal regimen is expected to be
efficacious and safe in all RR-TB patients, whether they have already received TB treatment or not. DST
may be needed at the start of treatment to diagnose the resistance pattern to determine whether a
particular regimen is indicated. Furthermore, DST will be needed for monitoring amplification of
resistance in an individual patient and resistance prevalence in a population.
In the optimal case, efficacy (bacteriological cure without relapse in at least 1-year follow-up, among
patients who are not lost to follow-up) should approach that of the standard WHO regimen for DS-TB.
Furthermore, it is expected that, as the efficacy of drugs included in the regimens increases, the total
number of drugs constituting the regimen can decrease. This should minimise the probability of drug–
drug interaction/toxicity and increase the ability to coformulate the individual drugs into fixed-dose
combinations. Decreased complexity of a RR-TB regimen will likely be readily accepted by national TB
programmes as they will be easier to implement.
TRP for pan-TB treatment
Rationale
A highly effective, safe and well tolerated three- to four-drug fully oral regimen that could be administered
to any TB patient regardless of drug resistance profile would revolutionise the treatment of TB [26]. To
allow for universal adoption, the regimens should be simple to administer (ideally once daily) and have
low propensity for drug–drug interactions. As there should be no or minimal prior resistance to the drugs
included in the regimen, it may be used empirically without the need for DST, eliminating treatment delays.
Key attributes
The intended use case assumes this simple, novel regimen is simultaneously studied and approved for
empirical use in both RS- and RR-TB patients with strains sensitive to the new drugs. This would be
particularly important in areas with high prevalence of MDR-TB and low availability of DST, where
patients may be treated inappropriately and continue to transmit disease for extended periods (table 3).
Forecasted role of TRPs for new regimens
The TRPs presented here describe the series of attributes that are considered essential for novel treatment
of TB, such as efficacy, safety, toxicity, drug–drug interactions and potential of acquisition of drug
resistance. Satisfying all of these characteristics in a single regimen, however, will be difficult to achieve in
the short term, and regimen developers might have to face trade-offs: for example, increasing efficacy (cure
rates) or safety versus shortening treatment duration, or making regimens simple and well tolerated versus
making them more complex and robust to emergence of drug resistance.
It should be understood that, for an infectious disease such as TB with a large global burden and ongoing
person-to-person transmission, the efficacy of the new regimens will depend heavily on operational factors
that also affect a regimen’s ability to fulfil its role (e.g. background antimicrobial resistance, resistance in
the MDR-TB patient population to important existing TB drugs, development of resistance to new drugs
and slow uptake of new drugs). For these reasons, these TRPs give indications on the respective attributes
to be considered at the developmental stage, but these should not be dissociated from the factors to be
considered at implementation stage.
All drugs used in a study regimen should meet either WHO prequalification or certification from a
stringent regulatory authority or be study drugs that are tested in a facility with good manufacturing
practice certification for quality assurance. It would be suitable that each individual drug component or
the regimen as a whole be approved for use in TB by at least one stringent regulatory authority. If a
regimen is recommended by the WHO using GRADE evidence review, it is expected that the regimen, or
its individual components, be widely available in quality assured formulations within 2 years.
Strategies to lower the regimen costs should be considered from the outset, with adherence to the principles
of access to medicine. Once a new regimen is established to be superior to current regimens in terms of
safety and/or efficacy, then stakeholders should continue to work to bring down the cost of the regimen by
working on costs of individual drugs, as well increasing the demand for the new regimen. Finally, it is
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TABLE 2 Characteristics of the target regimen profile for rifampicin-resistant (RR) tuberculosis (TB)
Attribute Minimum# Optimum¶
1 Indication The RR-TB regimen is indicated for patients
infected with RR strains (including MDR-TB)
Indication may be contingent upon additional
resistance to existing first- or second-line
drugs, and supported by appropriate DST
The RR-TB regimen is indicated for all patients
infected with RR-TB strains, with usage
consistent with principles of good antibiotic
stewardship
2 Efficacy and duration of treatment A 6–12-month treatment regimen Efficacy
(bacteriological cure without relapse in at
least 1-year follow-up, among patients who
are not lost to follow up) should be not
inferior to the WHO recommended standard
of care for MDR-TB
Less than or equal to 6-month treatment
regimen
Efficacy should be >90%
3 Target population in respect to age At least adolescent (age 12–19 years) and
adults
All age groups irrespective of severity of
disease, pulmonary or extrapulmonary TB, or
HIV status
4 Safety and tolerability SAEs no more than 5% and treatment
discontinuation due to TEAEs no more
than 2.5%
QT prolongation and proarrhythmic effects of
the regimen would not put the patient at a
moderate or high risk of arrhythmias or
sudden death
SAEs are no more than 2% and treatment
discontinuation due to TEAEs no more
than 2%
The regimen would have no or insignificant QT
prolongation or proarrhythmic effects
5 DDI and metabolism Ability to adjust dosing or perform safe
monitoring for DDIs with:
At least one first-line ART regimen
Drugs that induce or inhibit P450 liver enzymes
Pro-arrhythmic QT prolonging drugs
No dose adjustment with other medications and
ability to safely use without active laboratory
tests monitoring with:
ART regimens and co-trimoxizole
Drugs that induce or inhibit P450 liver enzymes
Pro-arrhythmic QT prolonging drugs
6 Formulation dosage, route of
administration and dosing (including
schedule)
Formulation to be oral for all drugs in regimen
Ability to deliver paediatric dosing of the
regimen
Twice-daily dosing and manageable food
restrictions
Formulation to be oral.
FDC formulations available (desirable to have
no weight adjustment for adults)
Paediatric (oral) and i.v. formulations must
also be available
Once-daily or intermittent dosing (preference
for once-weekly or only monthly as the
intermittency)
7 Stability/shelf-life 3 years for all drugs in the regimen
No cold chain requirements
5 years for all drugs in the regimen
No cold chain requirements
8 Special populations Adults and women of childbearing potential
Increased acceptable risk (benefits outweigh
the risk in most cases) for pregnancy
women, paediatrics and those with significant
renal or hepatic disease






Adults, paediatrics, women of childbearing
potential and pregnant women
Ability to use the regimen with patients with
significant renal disease







9 Barrier to emergence of drug
resistance (propensity to develop
resistance, generation of
cross-resistance)
New resistance to one or more drugs in the
regimen emerges in <2% of treatment
courses when taken as prescribed and when
no pre-existing resistance to the drugs in the
regimen exists
Essentially no acquired resistance (<0.1%)
when regimen is taken as prescribed and no
pre-existing resistance to the drugs in the
regimen exists
MDR: multidrug-resistant; DST: drug-susceptibility testing; WHO: World Health Organization; SAE: serious adverse event; TEAE: treatment-emergent
adverse event; DDI: drug–drug interaction; ART: antiretroviral therapy; FDC: fixed-dose combination; i.v.: intravenous. #: should be considered
as a potential go/no go decision point; ¶: should reflect what is needed to achieve broader, deeper, quicker global health impact.
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assumed that within a few years of release, the production for supply of the drugs in the new regimen could
be rapidly scaled up to match demand with a corresponding decrease in the price. It is also expected that a
new regimen will reduce nondrug cost aspects (e.g. monitoring visits, adherence, patient support and safety
aspects), thereby improving simplicity of use, and these benefits may offset increased drug costs.
In conclusion, the TRPs proposed in this document represent a milestone towards the development of new
regimens for the treatment of all forms of TB, and will serve consortia linking drug developers, academics,
researchers, public health institutions and nongovernmental organisations.
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